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Abstract
Background: It was the aim of this study to evaluate the antibacterial impact of two silver(I) carbohydrate
complexes with tripodal thioglycosides, namely tris[2-(β-D-thio-glucopyranosyl)ethyl]-amine-silver(I)-nitrate (3)
and tris[2-(α-D-thio-manno-pyranosyl)ethyl]-amine-silver(I)-nitrate (4), on five oral pathogenic bacterial strains.
Furthermore, cytocompatibility was tested using human gingival fibroblasts (HGF).
Methods: Minimum inhibitory concentrations (MIC) were determined on five oral pathogenic bacterial strains by using
the broth microdilution method: Fusobacterium nucleatum (ATCC 10953), Aggregatibacter actinomycetemcomitans
(ATCC 33384), Porphyromonas gingivalis (ATCC 33277), Streptococcus mutans (ATCC 25175) and Enterococcus faecalis
(DSMZ 20376). Furthermore, antimicrobial efficiency was tested using agar diffusion assays. To evaluate cytocompatibility,
human gingival fibroblasts (HGFs) were exposed to AgNO3 and complex 3 followed by a live/dead staining.
Results: MIC of the silver(I) complexes ranged between 0.625 and 5.0 mmol/L. The silver complexes 3 and 4 showed
higher antibacterial efficiency against all tested species than AgNO3. Antibacterial efficiency of complexes 3 and 4 on F.
nucleatum (≥18 mm) and A. actinomycetemcomitans (≥23 mm) was more pronounced than against P. gingivalis
(≥15 mm). Complex 3 (20 mM) induced the largest inhibition zones (30 to 31 mm) on Gram-negative strains. For
Gram-positive strains, the largest inhibition zones were achieved by complex 3 (20 mM/S. mutans: 28 mm, E.
faecalis: 18 mm). Complex 3 had a lower cytotoxic impact on HGFs compared to AgNO3 by the power of ten.
Conclusions: The findings suggest that silver(I) carbohydrate complexes 3 and 4 might function as novel
antimicrobial agents for the treatment of periodontal, carious or endodontic diseases.
Keywords: Silver complexes, Silver nitrate, Antibacterial efficiency, Fibroblasts
Background
The use of silver and silver complexes in medicine and
dentistry has attracted much interest over the last decades
although the beneficial antibacterial effect of this precious
metal has been known since ancient times [1–3].
Numerous fields of application were described that
benefit from the antibacterial, antiviral and antifungal
efficiency of silver ions including the treatment of
oral infectious diseases [4, 5]. These effects of silver
ions are based mainly on three mechanisms of action:
First, interaction of silver ions with the bacterial DNA;
second, destruction of the cell membrane and third,
blocking of essential enzymes causing disruption of elec-
tron transport [6, 7]. Therefore, the antimicrobial activity
of silver(I) complexes strongly depends on the ligand-
exchange ability of the complexes in order to release the
coordinated silver(I) ions [8].
Inflammatory periodontal disease and dental caries are
the two main reasons for tooth loss. Due to the infec-
tious character of these widespread diseases, antibacter-
ial agents play an important role in the treatment of
periodontal and carious lesions [9–11]. In particular with
regard to periodontal diseases, several in vitro studies
have been published in the literature that describe the
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antibacterial efficiency of silver containing agents
against periodontal species [12]. Also in restorative
dentistry, suppression of pathogenic species is a sig-
nificant step towards an effective therapy. For diag-
nostic purposes and treatment of caries and pulpitis
[13], different silver-containing materials were de-
scribed in the literature including dental adhesives
and primers [14, 15], root canal sealers [16] and
silver-loaded composite filling materials [17, 18].
Metal complexes substituted with carbohydrates are
also increasingly studied for biomedical applications
[19]. In 2006, silver(I) complexes based on tripodal
thioglycosides were synthesized and analyzed in vitro
by our group [20]. Despite the promising results, no
clinical applications have been performed so far. One
of the main advantages observed, besides their water
solubility and stability in solution, was the higher
cytocompatibility of the obtained complexes compared
to their appropriate silver salts. Those silver com-
plexes had significantly lower cytotoxic and antiprolif-
erative effects [20]. It could also be shown that the
tested silver(I) carbohydrate complexes had a broad
antibacterial spectrum against different bacterial spe-
cies. However, so far, these tests have not considered
important oral pathogenic species that are associated
with periodontal, carious and endodontic infections.
With this background, it was the aim of this study
to determine the antimicrobial efficiency of two spe-
cific carbohydrate based silver(I) complexes, tris[2-(β-
D-thio-glucopyranosyl)ethyl]-amine-silver(I)-nitrate (3)
and tris[2-(α-D-thio-manno-pyranosyl)ethyl]-amine-sil-
ver(I)-nitrate (4), on oral pathogenic species. Add-
itionally, we aimed to compare cytocompatibility of




The detailed description of the synthesis of the complexes
was given earlier [20] and is schematically shown in Fig. 1.
In brief, tris[2-(β-D-thio-glucopyranosyl-)ethyl]-amine-
silver(I)-nitrate (3) was prepared by dissolving 277 mg
(0.405 mmol) of the unprotected ligand (1) and 68.5 mg
(0.405 mmol) AgNO3 in water (5 mL) and stirring the so-
lution overnight. After filtration the solvent was evapo-
rated. By diffusion of acetone into a aqueous solution of
the raw product 310 mg (89 %) of colorless needles were
obtained. 1H NMR (400 MHz, D2O, DSS): 4.71 (d, 3H,
H-1, J1,2 = 9.8 Hz), 3.31 (t, 3H, H-2, J2,3 = 9.3 Hz), 3.40
(t, 3H, H-3, J3,4 = 9.5 Hz), 3.47 - 3.52 (m, 6H, H-4, H-5),
3.96 (d, 3H, H-6, J6,6′ = 12.2 Hz), 3.72 (dd, 3H, H-6′,
J5,6′ = 6.1 Hz), 3.25 (d, 3H, CH, J = 12.2 Hz), 3.06 (d, 3H,
CH, J = 15.1 Hz), 2.84-2.99 (m, 3H, CH), 2.61 (d, 3H,
CH, J = 13.7 Hz). 13C NMR (D2O, DSS): 88.88 (C1), 82.63
(C2), 79.51 (C3), 75.38 (C4), 71.85 (C5), 63.53 (C6),
53.30 (N-CH2-), 34.57 (S-CH2-). ESI-MS: m/z (%):
792.16 (100) (8)+, 630.09 (60) [M-C6H10O5]
+, 468.03
(70) [M-2(C6H10O5)]
+, 305.97 (95) [M-3(C6H10O5)]
+.
Anal. Calcd for C24H45AgN2O18S3: C, 33.77; H, 5.31;
N, 3.28. Found: C, 32.90; H, 5.68; N, 3.07 %. Complex
4 was prepared analogous starting from the D-man-
nose derived ligand 2.
Bacterial strains
Five oral pathogenic bacterial species were used for this
study. Gram-negative strains: Fusobacterium nucleatum
(ATCC 10953), Aggregatibacter actinomycetemcomitans
(NCTC 9710/DSM 8324) and Porphyromonas gingivalis
(ATCC 33277). Gram-positive strains: Streptococcus
mutans (ATCC 25175) and Enterococcus faecalis
(DSMZ 20376). The bacterial strains were cultivated for
24 h at 37 °C under appropriate (aerobic/anaerobic) con-
ditions in nutrient solution (SCHAEDLER-Broth; Oxoid,
Germany) enriched with vitamin K (Roche, Germany).
In the next step, the suspensions of bacteria in the loga-
rithmic growth phase were centrifuged (4000 rpm, 5
min/Sigma, Eppendorf, Germany), rinsed twice using
PBS (phosphate buffered saline/GIBCO, Germany) and
resuspended to obtain a bacterial density of 108 bacteria/
mL, that equals an optical density of 0.1 at 640 nm.
Antibacterial efficiency
MIC/MBC
To assess the susceptibility of oral pathogenic
bacteria to silver(I) complexes, minimum inhibitory
concentrations (MIC) and minimal bactericidal con-
centrations (MBC) were determined. For this pur-
pose, test agents were dissolved in SCHAEDLER
medium (Oxoid, Germany) to obtain a concentration
of 40 mM. Serial dilution was performed for all com-
pound solutions. Afterwards, 100 μL of each bacterial
suspension (see 2.2) were pipetted into wells of mi-
crotiter plates (Greiner, Germany) containing 100 μL
of the corresponding diluted compound solution.
After incubation at 37 °C for 24 h, the bacterial
growth was evaluated. The MIC represents the dilu-
tion stage in which no clouding of the test specimen
was observed. Pure SCHAEDLER medium served as
positive control, SCHAEDLER medium including the
same amount of the bacterial suspension as negative
control. To distinguish MCI from MBC, 100 μL of
each compound solution with concentrations below
MIC were spread onto a Petri dish with SCHAE-
DLER agar (Oxoid, Germany) and cultivated under
identical conditions. The concentration of the dilu-
tion series where no growth of bacteria was observed
was considered as MBC.
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Agar diffusion tests
To evaluate the antimicrobial concentration-related
efficiency of the silver(I) complexes, agar diffusion
tests were performed. The general procedure of this
test was described previously in the literature [21].
Briefly: 100 μL of each bacterial suspension (108 bac-
teria/mL) were pipetted and spread onto a Petri dish
with Schaedler agar (Oxoid, Germany). 100 μL of
each test fluid were then filled into a central hole
(diameter: 8 mm) of each Petri dish. After bacteria
specific incubation time (>48 h), the diameters of the
inhibition zones were measured. For positive (nega-
tive) control chlorhexidine (distilled water) was used.
Six specimens were prepared for each test fluid
(AgNO3; complex 3 and 4) with two different con-
centrations (10 mM and 20 mM).
Cytocompatibility
In vitro cytocompatibility tests were performed by ex-
posing the test agents to human gingival fibroblasts
(HGFs). These fibroblasts were obtained from a gin-
giva biopsy of a periodontal healthy female patient
(aged 42) by explant method. A written informed
consent form was signed by the patient. Beforehand
the study was approved by the Ethics Committee Jena
(#1881-10/06; Ethics Committee of the Friedrich-
Schiller-University Jena at the Medical Faculty, Bach-
strasse 18, 07740 Jena, Germany). HGF were chosen
since they play a very important role in collagen me-
tabolism and wound healing processes in periodontal
lesions.
The cells were cultivated at 37 °C with 5 % of CO2
using DMEM (Dulbecco’s Modified Eagle’s Medium)
with 10 % of fetal calf serum and 0.1 % of AAS (anti-
biotic antimycotic solution). In our earlier publication
[20] could be demonstrated that cytotoxicity and anti-
proliferative effects are not related to the type of
sugar substituted to the complex. Therefore, only
complex 3 was included in cytocompatibility tests of
the present study.
HGFs were applied onto sterile cover glasses with a
density of 8000 cells/cm2 and cultivated for 24 h
under culture conditions. Complex 3, its correspond-
ing ligand 1 and AgNO3 were diluted in DMEM to
obtain a concentration of 20 mM for each test agent.
Afterwards decimal serial dilution was conducted to
obtain final concentrations of 20 mM, 2.0 mM, 0.2
mM, 0.02 mM and 0.002 mM. In the next step, the
cell medium was removed from the cover glasses and
1 mL of each diluted test agent was applied to the
HGFs. Pure cell medium served as negative control.
After an incubation time of 24 h, the cell medium
and test agent were pipetted off and HGFs were
stained using a live/dead colorant (12 mL of PBS + 2
μL of fluorescein diacetate (vital) + 16 μL ethidium
bromide [EtBr] (dead)) and evaluated using a Labophot
microscope (Nikon, Japan) equipped with a 10xphase con-
trast objective (λex = 455 to 495 nm).
Statistical analysis
A t-test was performed using SPSS software (IBM; ver-
sion 19) to determine whether the differences between
inhibition zones of complex 3 and 4 compared to the
control (AgNO3) are significant. P values < 0.005 are
considered significant. The bars in the diagrams (Figs. 2
and 3) in which a statistically impact of the silver com-
plex compared to AgNO3 at the same concentration (10
mM or 20 mM) was found (p < 0.005) were marked (*).
Results
The antibacterial efficiency of silver(I) carbohydrate
complexes (GlcS-)3-N AgNO3 (3) and (ManS-)3-N
AgNO3 (4) against the tested bacterial strains Fusobac-
terium nucleatum, Aggregatibacter actinomycetemcomi-
tans, Porphyromonas gingivalis, Streptococcus mutans
and Enterococcus faecalis was more pronounced than
the effect of AgNO3.
Fig. 1 Schematic representation of the synthesis of the studied silver(I) complexes tris[2-(β-D-thio-glucopyranosyl)ethyl]-amine-silver(I)-nitrate (3)
and tris[2-(α-D-thio-manno-pyranosyl)ethyl]-amine-silver(I)-nitrate (4)
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MIC/MBC
The obtained MIC/MBC values of complexes 3, 4,
AgNO3 and free ligands for the selected bacterial strains
are shown in Table 1. For all tested bacterial species, in-
hibition of growth was observed by using silver com-
plexes and AgNO3. Gram-negative bacterial strains had
similar concentrations (MICs: P. gingivalis: 0.625 mM
[3], 1.25 mM [4]; A. actinomycetemcomitans: 0.625 mM
[3, 4] and F. nucleatum: 0.625 mM [3, 4]) compared to
AgNO3 (P. gingivalis: 0.625 mM, A. actinomycetemco-
mitans: 0.625 mM and F. nucleatum: 0.625 mM). It is
apparent that for Gram-positive species higher concen-
trations of the silver complexes (S. mutans: 10 mM [3],
20 mM [4] and E. faecalis: 10 mM [3], 20 mM [4]) are
necessary to achieve effective inhibition of bacterial
growth (MIC). For a complete suppression of bacteria
(MBC), higher concentrations of the tested agents were
essential in general. Also in this case a distinct difference
between Gram-negative (1.25 to 2.5 mM) and Gram-
positive (10 to 20 mM for complexes 3 and 4) species
was observed. No antimicrobial effect was observed for













































Fig. 2 Diameters and standard deviations of the inhibition zones caused by AgNO3, silver complexes 3 and 4 for three tested Gram-negative
bacterial species. No antibacterial effect was produced by the free ligands 1 and 2. Statistically significant differences compared to AgNO3












































Fig. 3 Diameters and standard deviations of the inhibition zones caused by AgNO3, the silver complexes 3 and 4 for two tested Gram-positive
bacterial species. No antibacterial effect was produced by the free ligands 1 and 2. Statistically significant differences compared to AgNO3 (same
concentration) are marked (*)
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Agar diffusion assay
This test showed that silver complexes 3 and 4 in-
hibit the growth of the tested oral pathogenic bacter-
ial strains. Diameters of the inhibition zones and
standard deviations are shown in Fig. 2 (Gram-nega-
tive) and 3 (Gram-positive bacterial strains).
For all tested Gram-negative bacterial strains (Fig. 2)
silver complexes 3 and 4 generated larger diameters of
inhibition zones (10 mM: 18 to 27 mm/20 mM: 16 to 31
mm) compared to AgNO3 (10 mM: 11 to 16 mm/20
mM: 16 to 20 mm). The largest inhibition zones were
found for complex 3. It is apparent that in most cases
the antibacterial efficiency against F. nucleatum and A.
actinomycetemcomitans was more pronounced than
against P. gingivalis.
In general, smaller inhibition zones were found for
Gram-positive bacterial strains (Fig. 3). It has been
shown that all tested agents have a greater antibacterial
impact on S. mutans compared to E. faecalis. The largest
inhibition zones were achieved by complex 3 (20 mM/S.
mutans: 28 mm, E. faecalis: 18 mm).
Cytocompatibility tests
Figure 4 shows representative images of the microscopic
analysis of the human gingival fibroblasts after being ex-
posed to silver complex 3, ligand 1 and AgNO3. It was
noted that AgNO3 has a cytotoxic impact on HGFs at a
concentration above 0.02 mM. For silver complex 3, re-
duced cytotoxicity by the power of ten was shown. No
cytotoxic impact on HGFs at all was observed for the
free ligand 1.
Discussion
Antiinfectious therapeutic agents play an important role
in almost every field of medicine. Besides the widespread
group of systemically applied classical antibiotics,
Table 1 Minimum inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) of the tested compounds on oral
pathogenic bacterial strains
Bacterial species Tested agent Concentration (mM)
20 10 5 2.5 1.25 0.625 0.312 0.156
F. nucleatum AgNO3 – – – – – + +
3 – – – – – – (+) + +
1 + + + + + + + +
4 – – – – – – (+) + +
2 + + + + + + + +
A. actinomycetem-comitans AgNO3 – – – – – – + +
3 – – – – – – (+) + +
1 + + + + + + + +
4 – – – – – – (+) + +
2 + + + + + + + +
P. gingivalis AgNO3 – – – – – – (+) + +
3 – – – – – (+) – + +
1 + + + + + + + +
4 – – – – – (+) + + +
2 + + + + + + + +
S. mutans AgNO3 – – – – (+) – (+) + + +
3 – – – (+) – (+) + + + +
1 + + + + + + + +
4 – – (+) – (+) – (+) – (+) + + +
2 + + + + + + + +
E. faecalis AgNO3 – – – – + + + +
3 – – – (+) + + + + +
1 + + + + + + + +
4 – – (+) – (+) + + + + +
2 + + + + + + + +
+ = Growth of bacteria, (+) = Growth after applying on agar Petri-dishes
- = No growth of bacteria
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alternative agents with antibacterial properties are in-
creasingly discussed in the literature. Metal complexes
are a promising class of materials with antimicrobial
properties. By substitution with sugar residues, metal
complexes can be modified to obtain higher levels of
solubility and cytocompatibility, which is essential for
their use in medicine [19, 22]. Similar silver(I) carbo-
hydrate complexes with tripodal thioglycosides were
synthesized and described in 2006 by Gottschaldt
et al. [20]. In order to evaluate their possible applica-
tion in dentistry, i.e. in periodontal, carious and end-
odontic treatment procedures, two silver complexes
were investigated in this in vitro study: Tris[2-(β-D-thio-glu-
copyranosyl)ethyl]-amine-silver(I)-nitrate (3) and tris[2-(α-
D-thio-manno-pyranosyl)ethyl]-amine-silver(I)-nitrate (4).
Fusobacterium nucleatum, Aggregatibacter actino-
mycetemcomitans and Porphyromonas gingivalis were
used in this study as they play an important role in
the etiology of periodontal diseases [23–25]. Strepto-
coccus mutans was included due to its strong associ-
ation with dental caries [18, 26]. Enterococcus
faecalis, a representative species of the gastrointes-
tinal flora, was also considered as it is the most fre-
quently isolated bacterial strain in re-infected and
insufficiently filled root canals [27, 28].
Relating to the inhibition zones of the agar diffusion
assays the novel silver(I) carbohydrate complexes 3 and
4 were able to suppress the growth of all tested Gram-
positive and Gram-negative bacterial species (Figs. 2 and
3) adequately in vitro. However, the results of the agar
diffusion assays should be interpreted for each test com-
pound separately, depending on the ability of the com-
plexes and AgNO3 to diffuse through the agarose gel.
MIC/MBC values (Tab. 1) showed that the Gram-
negative species F. nucleatum, A. actinomycetemcomi-
tans and P. gingivalis are more susceptible to the silver
complexes compared to the Gram-positive species S.
mutans and E. faecalis. Similar results were reported
previously underlining the higher efficiency of silver
ions against the Gram-negative bacterial species A. acti-
nomycetemcomitans, P. gingivalis P. intermedia and E.
corrodens [29, 30]. It is assumed that the superior be-
havior against Gram-negative strains is caused by the
lack of the thick protective peptidoglycan layer that can
be found in Gram-positive bacterial species [31].
In fields of periodontal therapy there is still need for
optimal antiinfectious agents [32]. It is well known that
for the treatment of periodontitis the mechanical re-
moval of subgingival biofilms by scaling and root planing
is more effective when combined with systemic or local
application of antibiotic agents [33, 34]. To avoid side ef-
fects and drug resistances caused by high doses of sys-
temically applied antibiotics [35], antimicrobial agents
that are applied directly in the periodontal pocket have
attracted increasing interest over the last years [21].
The adequate antibacterial effectiveness of silver
against periodontal pathogenic species was also shown
in several studies. Kawahara et al. [29] demonstrated
successfully the antibacterial effect of silver-zeolite
against oral pathogenic species under anaerobic condi-
tions to mimic the milieu of periodontal pockets. The
study of Lu et al. [36] also focused on the antibacterial
impact of differentially sized silver nanoparticles against
anaerobic bacteria. In this case, the smallest tested nano-
particles (5 nm) showed higher antimicrobial effects
compared to larger particles (15 to 55 nm). This
Fig. 4 Human gingival fibroblasts (HGFs) after exposure to a silver nitrate, b silver complex 3 and c its corresponding free carbohydrate ligand
1 in different concentrations. Due to live/dead staining vital cells appear green while dead cells are red
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suggests that also the small size of complexes 3 and 4 is
a relevant factor for the adequate antibacterial proper-
ties. Also the weak binding of silver to thio-ether func-
tions in complexes 3 and 4 leads to their high
antibacterial activity. Bacterial proteins function as sulfur
donor ligands that replace the ligands of the silver com-
plexes [20, 37].
The high antibacterial efficiency in vitro indicates that
the tested silver complexes 3 and 4 might be used as
beneficial active ingredients in various types of dental
materials. Since the early 20th century, the caries arrest-
ing effectiveness of silver nitrate, silver fluoride and sil-
ver diammine fluoride has been reported in numerous
studies [38–40]. It should be noted that in some studies,
black discolorations were observed using silver com-
pounds like silver fluoride in high concentrations (up to
40 %) [39, 41]. In the context of our in vitro investiga-
tions no black staining could be detected when the silver
complexes were in contact with DMEM medium or dur-
ing agar diffusion assays. However, in the course of con-
tinuative studies (in vitro, later in vivo) we will clarify if
silver complexes 3 and 4 also cause black discolorations
in appropriate concentrations.
Other studies focused on the modification of increas-
ingly applied dental composite filling materials [17, 18].
In 1999, Yoshida et al. reported on TEGDMA-UDMA
based resin composites containing 5 and 7 wt-% silver
supported active components, showing their antibacter-
ial efficiency against S. mutans for six months in water
while the mechanical qualities of the materials were not
negatively affected [16]. With the modification of silver
by synthesizing complexes like those used for this
study, especially regarding functional groups and
hydrophilic properties, material qualities of silver con-
taining resin-based composites might be optimized
while maintaining the antibacterial efficiency. Another
beneficial aspect is the anti-biofilm effect of silver that
was shown in numerous studies [18, 39, 42]. The sup-
pression of bacterial biofilms on surfaces of implants or
dental filling materials attracted much interest over the
last years as negative effects like periodontitis, periim-
plantitis, gingivitis and secondary caries can be reduced
[43, 44]. Further in vitro investigations of silver com-
plexes should, therefore, also focus on their influence
on dental plaque. It should be noted, however, that bac-
terial biofilms require considerably higher concentra-
tions of antibacterial compounds for an effective
removal [45]. Just like for classical antibiotics, the
tested silver complexes could not be used in excessive
concentrations to avoid cytotoxic side effects.
For E. faecalis, the diameters of the inhibition zones
resulting from complex 3 and control AgNO3 in lower
concentration (10 mM) are relatively small (10 to 11
mm). However, a clinical antibacterial benefit against E.
faecalis will most likely by achieved by complex 3 at
concentrations above 10 mM (Fig. 3). Since primarily
infected endodontic lesions posses a mixture of
Gram-positive and Gram-negative bacterial species,
disinfection of root canals might also be another field
of application in which the silver-complexes could
possibly be used. Besides mechanical preparation of
the root canals, chemical agents are required for the
debridement of infected root dentine. Next to the
most common irrigation agents like sodium hypo-
chlorite (NaClO) [46], in addition solutions containing
silver complexes might enhance chemical eradication
of the pathogen microorganisms. In 2008, Kreth et al.
[16] reported about the successful impregnation of
silver ions into endodontic sealers to achieve a more
profound antibacterial impact. Such approaches
should be considered in further studies to thwart the
residual bacteria in root canals, which may have re-
sulted in reinfection and treatment failure. The good
water solubility of the complexes 3 and 4 might also
enable their incorporation in well-established irriga-
tion agents as mentioned above.
The experiments show that complex 3 reveals a lower
cytotoxic impact compared to AgNO3 on human gin-
gival fibroblasts (HGF). HGF represent the predominant
cell type in the oral cavity. Particularly in the context of
wound healing in periodontal lesions, HGF play a very
important role due to their contribution in collagen me-
tabolism. On this account HGF were chosen for cyto-
compatibility investigations by our group and in other
studies [47, 48].
As shown before in a previous report, cytotoxicity
and antiproliferative effects are not related to the type
of sugar substituted to the complex [20]. Therefore,
only complex 3 was included in cytocompatibility tests
of the present study. However, the results of this study
are consistent with the cytotoxicity test performed
with other cell lines, L-929 (mouse fibroblasts) and
HeLa (human cervix carcinoma) in which silver com-
plexes had a significantly lower cytotoxic potential
compared to AgNO3 [20]. On the other hand, the min-
imal inhibitory concentrations (see Table 1) of the
tested bacterial strains are considerably higher than
the concentration of complex 3 (0.02 mM) in which no
cytotoxic impact on human gingival fibroblast was
found (Fig. 4). This might limit the spectrum of clinical
applications. In the treatment of periodontal lesions,
active compounds such as antibiotics are applied dir-
ectly in the periodontal pocket using drug carrier sys-
tems for a controlled release [49]. Also in endodontic
lesions, the cavity itself limits the field of action, so
that direct contact with keratinocytes and other cells is
the oral cavity is very unlikely especially when a dental
rubber dam is applied.
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The widespread use of silver, silver nano particles
and silver complexes in medical devices indicate ad-
equate biocompatibility. In a study of Zhao et al. [50],
the cytotoxic impact of silver nanoparticles on rat os-
teoblasts has been reduced by controlling the release
rate of silver from titania nanotubes. Also for the
tested silver complexes in this study, a controlled re-
lease would be essential for their possible application
in vivo to balance the ratio between antibacterial effi-
ciency and cytocompatibility.
Conclusion
The highly water soluble silver(I) carbohydrate com-
plexes (GlcS-)3-N AgNO3 (3) and (ManS-)3-N AgNO3
(4) have a greater antibacterial efficiency against the
tested bacterial strains Fusobacterium nucleatum, Aggre-
gatibacter actinomycetemcomitans, Porphyromonas gin-
givalis, Streptococcus mutans and Enterococcus faecalis
than AgNO3. Compared to silver nitrate, silver (I) com-
plex 3 possesses a lower cytotoxic effect on human gin-
gival fibroblasts. The results of this study suggest that
the innovative silver (I) complexes 3 and 4 represent
new potential antibacterial agents for use in various
treatment procedures of periodontal, carious and end-
odontic diseases.
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